Background: Hürthle cell carcinoma (HCC) is not typically iodine avid, raising questions regarding postoperative use of radioactive iodine (RAI). The aims of this study were to describe current practice patterns regarding the use of RAI for HCC and to assess its association with survival.
Methods: The National Cancer Data Base 1998-2006 was queried for all patients with HCC who underwent total thyroidectomy.